Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | CTH | P32929 | 1/20 | 0.46 |
| ▸ | PHLPP2 | Q6ZVD8 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11785416 | 0.98 | HMGB1 (0.60) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL686599 | 0.83 | CA12 (0.54) | HMGB1CXCL12KDM4EALDH1A1HPGD | |
| SCHEMBL89590 | 0.82 | CYP3A4 (0.52) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL122472 | 0.82 | HMGB1 (0.62) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL9753149 | 0.82 | CA5A (0.44) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL30706280 | 0.82 | HMGB1 (0.62) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL28268608 | 0.82 | KMT2A (0.68) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL6856399 | 0.80 | HMGB1 (0.60) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL19100976 | 0.80 | CA1 (0.61) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 | |
| SCHEMBL9353947 | 0.80 | CYP3A4 (0.67) | HMGB1CXCL12CYP3A4KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5908723-A | Recording sheets | XEROX CORPORATION (US) | 1999-06-01 | — | — | US | claimed |
| WO-2025104079-A1 | SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2025-05-22 | — | — | WO | disclosed |
| CN-115279730-B | 2, 5-Or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group, useful as medicaments | OM药物公司 | 2025-02-14 | — | — | CN | disclosed |
| EP-4118069-B1 | PARA-HYDROQUINONE DERIVATIVES AS VEGF, TNF AND/OR IL INHIBITORS FOR THE TREATMENT OF NEUROINFLAMMATORY DISEASES | OM PHARMA SA (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM PHARMA SA (CH) | 2023-05-18 | — | — | US | disclosed |
| EP-4118069-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | OM Pharma SA (CH) | 2023-01-18 | — | — | EP | disclosed |
| CN-115279730-A | 2, 5-or 2, 6-disubstituted hydroquinone derivatives having at least one carboxyl, sulfo or amido group useful as medicaments | OM药物公司 | 2022-11-01 | — | — | CN | disclosed |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | Alhamadsheh, Mamoun M. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-0875501-A2 | Alkylenediamine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1998-11-04 | — | — | EP | disclosed |
| EP-0869118-A1 | Pyrrolidine derivative, anti-ulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1998-10-07 | — | — | EP | disclosed |
| US-5814634-A | PEPTIC ULCERS, GASTRIC ULCERS | SHISEIDO CO. LTD. (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0802196-A1 | Alkylenediamine derivative, antiulcer drug, and antibacterial drug | SHISEIDO COMPANY LIMITED (JP) | 1997-10-22 | — | — | EP | disclosed |
| US-5241044-A | Soluble poly(p-phenylene)s | EDISON POLYMER INNOVATION CORPORATION (US) | 1993-08-31 | — | — | US | disclosed |
| US-4801735-A | LEUKOTRIENE INHIBITORS | LILLY INDUSTRIES LIMITED (GB) | 1989-01-31 | — | — | US | disclosed |
| US-4791049-A | RELEASE OF A 1,3,4-THIADIAZOLE-CONTAINING COMPOUND BY OXIDATION OF ITS HYDROQUINONE-TYPE MOIETY; INTERIMAGE EFFECT; SHARPNESS | FUJI PHOTO FILM CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
| US-4740453-A | Silver halide photosensitive material containing a compound capable of releasing a photographically useful group | FUJI PHOTO FILM CO., LTD. (JP) | 1988-04-26 | — | — | US | disclosed |
| EP-0183532-A2 | Pharmaceutical compounds | Lilly Industries Limited (GB) | 1986-06-04 | — | — | EP | disclosed |
| US-3943137-A | ANTITUMOR | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1976-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150951-A1 | 2,5- OR 2,6-DISUBSTITUTED HYDROQUINONE DERIVATIVES WITH AT LEAST ONE CARBOXY, SULFO OR AMIDO GROUP USEFUL AS MEDICAMENTS | HRH4, NCOA4, HRH3 | HMGB1 2177/4885CXCL12 2023/4885CYP3A4 474/4885 |
| US-11129902-B2 | Enhanced SN-38 anticancer agent | LENG8, TSG101, CD47 | HMGB1 682/4885CXCL12 1312/4885CYP3A4 3651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.